Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 20/20 | 0.82 |
| ▸ | TGM2 | P21980 | 20/20 | 0.82 |
| ▸ | TGM6 | O95932 | 1/20 | 0.80 |
| ▸ | F13B | P05160 | 1/20 | 0.80 |
| ▸ | TGM1 | P22735 | 1/20 | 0.80 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21486561 | 1.00 | F13A1 (0.82) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338785 | 0.95 | F13A1 (0.80) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338789 | 0.95 | F13A1 (0.80) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL21516583 | 0.95 | F13A1 (0.78) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338844 | 0.95 | F13A1 (0.78) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338737 | 0.95 | F13A1 (0.78) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338732 | 0.95 | F13A1 (0.78) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338806 | 0.94 | F13A1 (0.77) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338799 | 0.94 | F13A1 (0.77) | F13A1TGM2TGM6F13BTGM1 | |
| SCHEMBL20338871 | 0.92 | F13A1 (0.74) | F13A1TGM2TGM6F13BTGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | claimed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | claimed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | F13A1 209/4885TGM2 1/4885TGM6 4/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | F13A1 209/4885TGM2 1/4885TGM6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.